醋酸甲地孕酮治疗恶病质症状。

文章的细节

引用

复制到剪贴板

Berenstein如Ortiz Z

醋酸甲地孕酮治疗恶病质症状。

科克伦数据库系统启2005年4月18日;(2):CD004310。

PubMed ID

15846706 (在PubMed

]

文摘

背景:醋酸甲地孕酮(MA)目前用于改善食欲,增加体重在癌症相关的厌食症。马在1993年被美国联邦药品管理局批准用于治疗厌食症,恶病质或原因不明的体重减轻艾滋病患者。马的机制增加食欲是未知的,和其有效性厌食症和恶病质肿瘤和艾滋病患者正在调查中。目的:评估疗效,有效性和安全性的马减轻恶病质症状患者的癌症,艾滋病和其他潜在疾病。必威国际app搜索策略:研究寻求全面广泛搜索的电子数据库、期刊、参考列表,与调查人员和其他搜索策略中概述的方法。最近的2002年10月进行搜索。必威国际app选择标准:研究均包括在审查评估醋酸甲地孕酮相比安慰剂或其他药物治疗的随机对照试验厌食的临床诊断恶病质患者相关癌症、艾滋病或其他潜在的病理。数据收集和分析:数据提取是由两个独立的作者,和方法学质量评价。定量分析使用偏好和生活质量作为一个二分变量,并分析了体重增加连续和二分变量。研究有超过50%的患者失访被排除在分析之外。 MAIN RESULTS: Thirty trials met the inclusion criteria (4123 patients). Twenty-one trials compared MA at different doses with placebo; four compared different doses of MA versus other drugs; two compared MA with other drugs and placebo; and three compared different doses of MA. For all patient conditions, meta-analysis showed a benefit of MA compared with placebo, particularly with regard to appetite improvement and weight gain in cancer patients. Analysing quality of life, clinical and statistical heterogeneity was found and discussed. There was insufficient information to define the optimal dose of MA. AUTHORS' CONCLUSIONS: This review demonstrates that MA improves appetite and weight gain in patients with cancer. No overall conclusion about quality of life (QOL) could be drawn due to heterogeneity. The small number of patients, methodological shortcomings and poor reporting have not allowed us to recommend megestrol acetate in AIDS patients or with other underlying pathologies.

DrugBank数据引用了这篇文章

药物

醋酸甲地孕酮